Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29971157 | 1.00 | TAAR1 (0.33) | TAAR1DAOADRB2CYP3A4HSD17B10 | |
| SCHEMBL23409587 | 0.83 | HSD17B10 (0.38) | CYP3A4HSD17B10ADRA2AADRA2CADRA1A | |
| SCHEMBL29970962 | 0.83 | HSD17B10 (0.38) | CYP3A4HSD17B10ADRA2AADRA2CADRA1A | |
| SCHEMBL22437279 | 0.80 | TAAR1 (0.37) | TAAR1ADRB2CYP3A4HSD17B10ADRA2A | |
| SCHEMBL23409597 | 0.80 | ALDH1A1 (0.36) | CYP3A4HSD17B10ADRA1A | |
| SCHEMBL23409499 | 0.80 | DRD4 (0.30) | — | |
| SCHEMBL29970456 | 0.80 | ALDH1A1 (0.36) | CYP3A4HSD17B10ADRA1A | |
| SCHEMBL29969345 | 0.80 | DRD4 (0.30) | — | |
| SCHEMBL7629009 | 0.72 | HPGD (0.34) | TAAR1CYP3A4HSD17B10ADRA2AADRA2C | |
| SCHEMBL3082888 | 0.70 | TSHR (0.35) | TAAR1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466781-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115279359-A | Novel thyromimetic agents | 速通医疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4065098-A1 | NOVEL THYROMIMETICS | Autobahn Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048992-A1 | NOVEL THYROMIMETICS | TSHR, TPO, CHRM1 | TAAR1 13/4885DAO 1719/4885ADRB2 43/4885 |
| US-12466781-B2 | Thyromimetics | TPO, TSHR, CHRM1 | TAAR1 14/4885DAO 1668/4885ADRB2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.